Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Två genombrott i behandling av typ 2-diabetes. Både receptoragonist och enzymhämmare har nu nått kliniken.

Ahrén, Bo LU (2007) In Läkartidningen 104(49-50). p.3763-3764
Please use this url to cite or link to this publication:
@article{f1fc2c61-4ee5-4e15-a7a5-c8e5261f65fd,
  author       = {{Ahrén, Bo}},
  issn         = {{0023-7205}},
  keywords     = {{Type 2: drug therapy; Enzyme Inhibitors: administration & dosage; Enzyme Inhibitors: therapeutic use; Glucagon-Like Peptide 1: metabolism; Hypoglycemic Agents: administration & dosage; Hypoglycemic Agents: therapeutic use; Nitriles: administration & dosage; Nitriles: therapeutic use; Peptides: administration & dosage; Peptides: therapeutic use; Pyrrolidines: administration & dosage; Pyrrolidines: therapeutic use; Receptors; Glucagon: drug effects; Venoms: therapeutic use; Venoms: administration & dosage; Diabetes Mellitus; CD26: antagonists & inhibitors; Antigens; Adamantane: therapeutic use; Adamantane: administration & dosage; Adamantane: analogs & derivatives}},
  language     = {{swe}},
  number       = {{49-50}},
  pages        = {{3763--3764}},
  publisher    = {{Swedish Medical Association}},
  series       = {{Läkartidningen}},
  title        = {{Två genombrott i behandling av typ 2-diabetes. Både receptoragonist och enzymhämmare har nu nått kliniken.}},
  url          = {{http://www.ncbi.nlm.nih.gov/pubmed/18214322?dopt=Abstract}},
  volume       = {{104}},
  year         = {{2007}},
}